📅 PUBMED DAILY TRIAGE — 2026-05-09

Window: 2026-05-08T09:00:00Z → 2026-05-09T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~100 candidates | Candidates evaluated: 100 High priority: 2 | Standard: 10 | Low/archive: ~88 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

TR-2026-05-09-001 / PMID 42102826 · Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: NordICC multicountry RCT · 9/10 · 🔴 EARLY_CANCER_DETECTION

The definitive 13-year, n=84,583 colonoscopy RCT (Lancet): one colonoscopy cut CRC incidence by 19% (intention-to-screen) or 45% (per-protocol) but failed to show statistically significant mortality benefit in ITT analysis — directly reshaping colonoscopy's place in CRC screening algorithms globally.

TR-2026-05-09-002 / PMID 42102976 · A Multi-Analyte cfDNA-based Blood Test (HelioLiver Dx) for Early Detection of Hepatocellular Carcinoma · 9/10 · 🔴 EARLY_CANCER_DETECTION

First blinded multicenter prospective validation (n=1,268 with cirrhosis, J Hepatol): HelioLiver Dx achieved 47.8% sensitivity vs 28.3% for ultrasound overall, and 28.6% vs 0% for small HCC ≤2 cm — met prespecified co-primary endpoints; could displace ultrasound surveillance in high-risk patients.

🟢⚪ STANDARD (5-7) — Top by Topic

AI/ML in Clinical Diagnostics and Imaging

• TR-2026-05-09-003 / PMID 42104391 · Agentic GPT-5.0 outperforms human experts in ICU decisions (simulation study) · 7/10 · AI/ML Diagnostics — Agentic multi-LLM architecture (GPT-5.0 + Gemini 2.0) achieved 91.0% accuracy on acid-base vignettes vs 83.0% for physicians; SSC bundle compliance 96.8% vs 90.4%. Simulation only — requires real-world validation.
• TR-2026-05-09-009 / PMID 42104431 · ML to predict axillary lymph node metastasis in breast cancer using immune profiles (AUC 0.84) · 6/10 · Diagnostics — CD21+ follicular dendritic cells emerged as top predictor, outperforming tumor diameter; Random Forest + SHAP; n=427 retrospective.
• TR-2026-05-09-010 / PMID 42103277 · Multi-omics ML for ACS/CCS diagnosis in young patients (AUC 0.95-0.99, n=206) · 6/10 · Diagnostics/Cardio-metabolic — Novel gut microbiome (Streptococcus parasanguinis) and metabolomic biomarkers; near-perfect AUC suggests overfitting risk; external validation required.
• TR-2026-05-09-011 / PMID 42104441 · Interpretable XGBoost model for HFpEF risk in COPD (AUC 0.898, n=1,619) · 6/10 · Diagnostics — External validation n=69 limits confidence; red blood cell count among 9-feature panel; NT-proBNP top predictor.

Hematologic Malignancies

• TR-2026-05-09-007 / PMID 42104236 · Proteomic/phosphoproteomic signatures of UM-IGHV CLL disease progression (Mayo Clinic, n=18) · 6/10 · Diagnostics — 6,300+ proteins; RNA processing pathways enriched in progressive CLL; hypothesis-generating biomarker candidates.
• TR-2026-05-09-008 / PMID 42104100 · MRD conversion during oral azacitidine maintenance in favorable-risk AML (multicenter, n=30) · 6/10 · Treatment Innovation — 64% MRD conversion rate; persistent MRD predicted early relapse (24mo RFS 63 days); salvage ven/aza effective.
• TR-2026-05-09-013 / PMID 42104158 · WT1 mRNA in peripheral blood for VEN/AZA response monitoring in AML (OHSG multicenter) · 5/10 · Diagnostics — Early WT1 reduction and negativity independently predict OS/PFS; retrospective; n unreported.

Aging, Longevity, and Population Health

• TR-2026-05-09-004 / PMID 42103698 · APOE2 promotes DNA repair pathways resisting senescence in human neurons (Buck Institute) · 6/10 · Genomics/Precision Medicine — iPSC-derived neuron model; APOE2 vs APOE4 isogenic comparison; mechanistic insight into longevity/AD protection.
• TR-2026-05-09-005 / PMID 42104437 · BMI and epigenetic aging: Mendelian randomization + NHANES cross-population study · 6/10 · Prevention — MR establishes causal link; physical activity mediates 10-16% of effect; women more vulnerable at same BMI; actionable.
• TR-2026-05-09-014 / PMID 42103376 · Frailty and healthcare utilization in adults ≥50y: LOFUS n=10,154 · 5/10 · Public Health — Frail patients have higher overall hospitalization (OR 1.27) but ACSC/non-ACSC distinction loses meaning; policy implications.

Rare Diseases with High Unmet Need

• TR-2026-05-09-006 / PMID 42103584 · Genomic newborn screening paradigm shift for rare endocrine conditions (France FIRENDO multicenter) · 6/10 · Genomics/Precision Medicine — WGS integration into France's national Genomic Medicine 2025 plan; pre-symptomatic diagnosis of rare endocrine disorders.

CBC-based Diagnostics and ML in Hematology

• TR-2026-05-09-012 / PMID 42104043 · AI bone marrow cell recognition: anticoagulant type significantly affects consistency (Sci Rep) · 5/10 · Diagnostics — Critical design implication for fully automated bone marrow AI devices; anticoagulant choice must be standardized.

💡 UNSOLICITED FINDS

None this run. All high-signal articles captured within watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 8 articles
• Early Detection: 2 articles (both HIGH)
• Prevention: 2 articles
• Genomics/Precision Medicine: 2 articles
• Treatment Innovation: 1 article
• Public Health: 1 article

By evidence maturity:

• Exploratory: 8 articles
• Validated: 4 articles
• Potentially Practice-Changing: 1 article (PMID 42102826, Lancet RCT)

By watchlist topic (reviewed / kept / highest score):

• Hematologic malignancies: 10 / 3 / 6
• CBC-based diagnostics and ML: 10 / 1 / 5 — ⚠️ 17th consecutive empty HIGH-priority window
• Early cancer detection: 10 / 2 / 9 ← Best topic this run
• AI/ML in clinical diagnostics: 10 / 4 / 7
• Precision oncology/genomics: 10 / 1 / 5
• Novel therapeutics (immunotherapy/CAR-T): 10 / 0 / 5 — No HIGH articles today
• Cardiovascular-metabolic: 10 / 2 / 6
• Aging/longevity: 10 / 3 / 6
• Rare diseases: 10 / 1 / 6
• Sentinel scan: 10 / 1 / 9 (PMID 42102826 confirmed)

By source type: peer_reviewed: 14 | preprint: 0

Topics with zero 8+ articles this run: Hematologic malignancies, CBC/ML hematology, AI/ML diagnostics, Precision oncology, Novel therapeutics, Cardiovascular-metabolic, Aging/longevity, Rare diseases

🔧 RUN NOTES

• Window: No expansion triggered (14 kept records, well above 5-article threshold)
• Deduplication: All new PMIDs (42101xxx–42104xxx range) confirmed novel vs state.json (previous max PMID: 42098477)
• humans[MeSH] filter: Applied to Aging/longevity topic per v1.2 spec (introduced 2026-05-04 run to reduce non-human noise); 41 results returned vs ~56 unfiltered — filter effective
• CBC/ML hematology: 17th consecutive empty HIGH-priority window; PMID 42104043 is the best find (score 5) — this topic continues to underperform for high-priority signal
• Notable: Two SCORE-9 articles in the same run is unusual — both from Early Cancer Detection topic (Lancet colonoscopy RCT + J Hepatol HCC blood test). Strong day for cancer screening.
• Novel therapeutics: CAR-Mac glioblastoma (PMID 42104273, score 5) was strongest but all preclinical; no clinical-stage novel therapeutic this run
• Cardiovascular-metabolic: No GLP-1/SGLT2 specific high-signal articles; ML diagnostic models (multi-omics young ACS, HFpEF in COPD) captured as STANDARD
• Rolling note (7-day): CBC/ML hematology has produced 0 HIGH articles in the last 17 runs; Cardiovascular-metabolic produced 0 HIGH articles today after strong showing on 2026-05-08 (SGLT2i meta-analysis, HF hospitalization)